Effect of pravastatin on serum levels of matrix metalloproteinases-1, matrix metalloproteinases-9 in patients underwent percutaneous coronary intervention / 第三军医大学学报

ABSTRACT

Objective To investigate the influence of pravastatin on serum matrix metalloproteinases-1(MMP-1), MMP-9 and its role in prevention of restenosis following coronary intervention. Methods Totally 62 patients after percutaneous coronary intervention (PCI) were randomly assigned to receive 10 mg/d pravastatin in 24-48 h after PCI for 6 months (n=32) or no therapy (n=30) as control. The blood samples of all patients were examined at admission and 7, 21 d after administration of pravastatin. All patients received follow-up and coronary checking within 6 months. Results TIMI 3 flow was achieved in all cases and residual stenosis was less than 20%. No severe complications were found. ①The use of pravastatin after PCI could significantly reduce serum levels of MMP-1 and MMP-9 as compared with control group (P